NCT00074854 - A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2002

Study Completion Date

March 31, 2005

Conditions

Lung Neoplasms

Interventions

DRUG

CP-547,632

Trial Locations (20)

11794

Pfizer Investigational Site, Stony Brook

19111

Pfizer Investigational Site, Philadelphia

37066

Pfizer Investigational Site, Gallatin

37076

Pfizer Investigational Site, Hermitage

37087

Pfizer Investigational Site, Lebanon

37130

Pfizer Investigational Site, Murfreesboro

37167

Pfizer Investigational Site, Smyrna

37203

Pfizer Investigational Site, Nashville

37205

Pfizer Investigational Site, Nashville

37207

Pfizer Investigational Site, Nashville

37211

Pfizer Investigational Site, Nashville

70002

Pfizer Investigational Site, Metairie

70006

Pfizer Investigational Site, Metairie

70115

Pfizer Investigational Site, New Orleans

70433

Pfizer Investigational Site, Covington

94402

Pfizer Investigational Site, San Mateo

94806

Pfizer Investigational Site, San Pablo

94904

Pfizer Investigational Site, Greenbrae

33612-9497

Pfizer Investigational Site, Tampa

02215

Pfizer Investigational Site, Boston